PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22840925-0	2013	"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-gamma production associate with drug response in patients with Crohn"s Disease.	Azathioprine	11-23	interferon gamma	Homo sapiens	75-84	
14992447-0	2004	Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn"s disease on AZA therapy.	Azathioprine	159-162	interferon gamma	Homo sapiens	95-111	
21083588-7	2011	Azathioprine therapy did not impair natural killer degranulation, but reduced natural and cytokine-activated cytotoxicity and interferon-gamma (IFN-gamma) production.	Azathioprine	0-12	interferon gamma	Homo sapiens	126-142	
21083588-7	2011	Azathioprine therapy did not impair natural killer degranulation, but reduced natural and cytokine-activated cytotoxicity and interferon-gamma (IFN-gamma) production.	Azathioprine	0-12	interferon gamma	Homo sapiens	144-153	
21083588-8	2011	Culture of resting peripheral blood mononuclear cells with azathioprine resulted in loss of natural killer cells and inhibition of activation and IFN-gamma production.	Azathioprine	59-71	interferon gamma	Homo sapiens	146-155	
19584951-8	2009	Prednisone and azathioprine treatment decreased total serum IgG, IgE, IFN-gamma and IL-4 levels, and blood CD19+ and CD23+ cells; however serum IL-12, TNFalpha and blood CD4+ T cells increased with treatment.	Azathioprine	15-27	interferon gamma	Homo sapiens	70-79	
1655916-5	1991	In the early post Tx period, the administration of antithymocyte globulin (ATG) or OKT3 monoclonal antibody and peak dosages of azathioprine were associated with significantly inhibited in vitro IFN-gamma production.	Azathioprine	128-140	interferon gamma	Homo sapiens	195-204	
2495253-3	1989	Following in vitro exposure to IFN-gamma an increase in NK activity from 36 to 44% (P less than 0.05) could be induced during CsA therapy but this was no longer observed after conversion to AZA (19 to 22%, N.S.).	Azathioprine	190-193	interferon gamma	Homo sapiens	31-40	
2495253-5	1989	The IFN-gamma production capacity after mitogen stimulation of unprimed lymphocytes was more depressed during CsA than during AZA therapy (median 25 vs 80 U/ml 10(6) cells, P less than 0.05), suggesting a reversible inhibition of CsA on lymphokine production.	Azathioprine	126-129	interferon gamma	Homo sapiens	4-13	
2495253-6	1989	Despite the better IFN-gamma production capacity, both the activity, inducibility and number of NK cells were significantly lower under AZA therapy than under CsA therapy.	Azathioprine	136-139	interferon gamma	Homo sapiens	19-28	
3920961-0	1985	Effects of treatment with azathioprine and cyclosporin A on interferon-gamma production by peripheral blood leukocytes of renal allograft recipients.	Azathioprine	26-38	interferon gamma	Homo sapiens	60-76	
3920961-2	1985	Both under immunosuppressive treatment with azathioprine and with cyclosporin A (CsA) the PBMC of these patients proved deficient for IFN-gamma production when compared to those of healthy controls.	Azathioprine	44-56	interferon gamma	Homo sapiens	134-143	
3920961-3	1985	After conversion from conventional azathioprine to CsA medication the ConA-induced IFN-gamma production increased.	Azathioprine	35-47	interferon gamma	Homo sapiens	83-92